Effectiveness and safety of secukinumab treatment in real-world clinical settings in European countries confirms its efficacy and safety from clinical trials: Data from an interim analysis of SERENA study - 22/08/19
Matthias Augustin, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg, Germany; Ralph von Kiedrowski, Company for Medical Study & Service Selters (CMS3) GmbH, Selters, Germany; Dimitris Rigopoulos, Dermatology and Venerology, National and Kapodistrian University of Athens, Medical School, Athens, Greece; Paul-Gunther Sator, Department of Dermatology, Municipal Hospital Hietzing, Vienna, Austria; Roberto Orsenigo, Novartis Farma S.p.A., Origgio, Italy; Justyna Veit, Novartis Pharma GmbH, Nuremberg, Germany; Maher Aassi, Novartis Pharma AG, Basel, Switzerland; Piotr Jagiello, Novartis Pharma AG, Basel, Switzerland
Le texte complet de cet article est disponible en PDF. Supported by Novartis Pharma AG, Basel, Switzerland. |
Vol 81 - N° 4S1
P. AB50 - octobre 2019 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?